I

Immunai

140 employees

Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Artificial Intelligence
cancer
software engineering
immunology
high-dimensional statistics
Therapeutics
Analytics
single-cell biology
Machine Learning
genomic technologies
machine learning

Date founded

2019

Funding rounds raised

Total raised

$215M

from 10 investors over 10 rounds

I

Immunai raised $215M on October 27, 2021

Investors: Meron Capital, Koch Disruptive Technologies, 8VC and ICon Professional Services

I

Immunai raised $60M on February 11, 2021

Investors: Meron Capital, TLV Partners, Catalio Capital Management and Dexcel Pharma

I

Immunai raised $20M on May 14, 2020

Investors: Meron Capital and TLV Partners

FAQ